(NASDAQ: REGN) and Sanofi (NASDAQ:SNY) have reported positive outcomes from a Phase 3 trial of Dupixent (dupilumab) in patients with chronic spontaneous ... reduced itch and hive activity scores ...
in patients with chronic spontaneous urticaria (CSU) who have not responded adequately to antihistamines. The results, presented at the American College of Allergy, Asthma & Immunology Annual ...
Recent studies estimate that Chronic Kidney Disease (CKD) affects 10% of the world’s population[1 ... One of its most common yet often overlooked disruptive condition is CKD-associated pruritus ...